Published 31 October 2008, doi:10.1136/bmj.a1864
Cite this as: BMJ 2008;337:a1864

Research

Patients’ preferences within randomised trials: systematic review and patient level meta-analysis

Objective To systematically review fully randomised patient preference trials and to explore the impact of preferences on attrition and outcome by meta-analysis of patient level data.

Data sources Citation search using Science Citation Index and Google Scholar and search of the main electronic databases (Medline, CINAHL, Embase, and AMED) with a combination of key words.

Study selection Fully randomised patient preference trials that compared treatments for any clinical condition were included. Other types of preference trials and crossover trials were excluded. Other inclusion criteria: participants aged 16 years and over; primary, self-reported outcomes measured on a continuous numerical scale. From 167 studies identified and screened, 17 were identified as fully randomised patient preference trials.

Data synthesis Of the 17 trials identified, 11 authors provided raw data for the meta-analysis. Data collected were baseline and follow-up data for the main outcome, randomised allocation data, preference data, and demographic data. Baseline and first post-intervention follow-up data for the main outcome were standardised. To improve homogeneity, data for only the eight musculoskeletal trials (n=1594) were combined. To estimate the effects of preferences on outcomes and attrition, three groups were compared: patients who had a preference and were randomly allocated to their preferred treatment; patients who had a preference and were randomly allocated to the treatment they did not prefer; and patients who had no preference.

Results Patients who were randomised to their preferred treatment had a standardised effect size greater than that of those who were indifferent to the treatment assignment (effect size 0.162, 95% confidence interval 0.011 to 0.314; P=0.04). Participants who received their preferred treatment also did better than participants who did not receive their preferred treatment (effect size 0.152, –0.035 to 0.339), although this was not statistically significant (P=0.11). Participants allocated to their undesired treatment had outcomes that were no different from those who were indifferent. Participants who were allocated to their undesired treatment were less likely to be lost to first follow-up compared with indifferent participants (odds ratio 1.70, 1.076 to 2.693; P=0.02). No difference was found in attrition between patients allocated to their preference and those who were indifferent.

Conclusions Preferences among patients in musculoskeletal trials are associated with treatment effects. In open randomised trials, preferences should be ascertained before randomisation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Do patients’ preferences matter?

Klim McPherson
BMJ 2008 337: a2034. [Extract] [Full Text]

United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care

UK BEAM Trial Team
BMJ 2004 329: 1377. [Abstract] [Full Text] [PDF]

Incorporating patient preferences into clinical trials

Klim McPherson, Iain Chalmers, Sarah Clement, Jim Sikorski, Jennifer Wilson, Bridget Candy, David J Torgerson, and Bonnie Sibbald
BMJ 1998 317: 78. [Extract] [Full Text]

Understanding controlled trials: What is a patient preference trial?

David Torgerson and Bonnie Sibbald
BMJ 1998 316: 360. [Full Text]

This article has been cited by other articles:

• (2008). Patient Preferences for Treatments Can Affect Outcomes of Randomized Trials. JWatch General 2008: 5-5 [Full text]  
• McPherson, K. (2008). Do patients' preferences matter?. BMJ 337: a2034-a2034 [Full text]  

Rapid Responses:

Read all Rapid Responses

Null Seeking Trials

Patrick Mitchell
bmj.com, 13 Jan 2009 [Full text]

Online poll

Find out more >>